AHCYP2: The Hint at a Potential Drug Target in Parks and Home Sets

Target Name: AHCYP2

NCBI ID: G392387

AHCYP2

Other Name(s): adenosylhomocysteinase pseudogene 2 | Adenosylhomocysteinase pseudogene 2

AHCYP2: The Hint at a Potential Drug Target in Parks and Home Sets

Introduction

AHCYP2 (adenosylhomocysteinase pseudogene 2) is a gene that encodes a protein located in the endoplasmic reticulum (ER) of the cell. The ER is a membrane-wrapped organelle that contains enzymes that synthesize and modify proteins within the cell. The protein encoded by the AHCYP2 gene is an enzyme responsible for degrading a class of molecules called AdoCystein. Under normal circumstances, AdoCystein is degraded into small molecule uracil nucleotides, thereby performing important biological functions within cells. However, in certain disease states, the AHCYP2 gene can mutate, causing changes in the structure or function of the protein it produces. These abnormal proteins may become drug targets or biomarkers.

Function and disease of AHCYP2 gene

Variations in the AHCYP2 gene are closely related to some diseases. Many studies have found that variations in the AHCYP2 gene are highly correlated with some neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are caused by excessive accumulation of AdoCystein molecules.

In addition, mutations in the AHCYP2 gene are also associated with the occurrence of some cancers. For example, studies have shown that variations in the AHCYP2 gene are related to the prognosis of certain types of cancer, including lung, liver, and kidney cancer. These mutated proteins may become biomarkers for cancer diagnosis and treatment.

Drug target or biomarker research on AHCYP2 gene

With the continuous development of science and technology, research on the AHCYP2 gene has gradually deepened. Many researchers believe that the AHCYP2 gene is a potential drug target and may become an effective means of treating certain diseases in the future.

First, mutations in the AHCYP2 gene may lead to changes in the structure or function of the protein it encodes. These abnormal proteins may become drug targets. For example, AdoCystein is a molecule related to neurodegenerative diseases that can be used as a drug target to treat Alzheimer's disease. In addition, mutations in the AHCYP2 gene may also be related to the occurrence of some cancers. These mutated proteins may become biomarkers for cancer diagnosis and treatment.

Secondly, variations in the AHCYP2 gene may also be related to the pathogenesis of some diseases. For example, excessive accumulation of AdoCystein is an important cause of some neurodegenerative diseases. Therefore, by studying the variation of the AHCYP2 gene, we can better understand the pathogenesis of these diseases and provide new ideas for treatment.

Summarize

In summary, AHCYP2 (adenylate acylase pseudogene 2) is a potential drug target or biomarker. By studying the variation of the AHCYP2 gene, we can better understand the pathogenesis of some diseases and provide new ideas for treatment.

Protein Name: Adenosylhomocysteinase Pseudogene 2

The "AHCYP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AHCYP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets